Upstream Bio, Inc. Cash Flow-to-Debt Ratio
Upstream Bio, Inc. cash flow-to-debt ratio. Upstream Bio, Inc. (UPB) has a Cash Flow-to-Debt Ratio of -3.49x as of June 2026, meaning its operating cash flow of $-35.62 Million could theoretically repay -3% of its total liabilities ($10.21 Million) in one year. See UPB financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Upstream Bio, Inc. (2022–2025)
Cash flow-to-debt ratio of Upstream Bio, Inc. from 2022 to 2025. Historical debt coverage capacity for Upstream Bio, Inc. across 4 annual periods. Also explore Upstream Bio, Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Upstream Bio, Inc. Cash Flow-to-Debt Ratio by Year (2022–2025)
Upstream Bio, Inc. cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Upstream Bio, Inc.. For the full cash flow conversion analysis, see cash flow conversion of Upstream Bio, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -9.52x | $-133.28 Million | $14.00 Million | ▼ -90.9% |
| 2024 | -4.99x | $-59.17 Million | $11.87 Million | ▼ -3059.6% |
| 2023 | -0.16x | $-37.93 Million | $240.32 Million | ▼ -3.4% |
| 2022 | -0.15x | $-19.02 Million | $124.63 Million | — |